6,171 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 6,171 shares of the biopharmaceutical company’s stock, valued at approximately $432,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Steph & Co. grew its position in Gilead Sciences by 1.9% during the 4th quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after acquiring an additional 142 shares during the last quarter. First Affirmative Financial Network raised its holdings in shares of Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares during the last quarter. Rathbones Group PLC grew its holdings in Gilead Sciences by 3.7% during the 4th quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock worth $339,000 after acquiring an additional 150 shares during the last quarter. MCF Advisors LLC lifted its position in shares of Gilead Sciences by 2.1% during the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 152 shares in the last quarter. Finally, Affinity Investment Advisors LLC increased its holdings in shares of Gilead Sciences by 0.8% in the fourth quarter. Affinity Investment Advisors LLC now owns 18,946 shares of the biopharmaceutical company’s stock valued at $1,535,000 after purchasing an additional 157 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on GILD. Truist Financial increased their price objective on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a research report on Thursday. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday, April 24th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday. Finally, Barclays cut their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.94.

Gilead Sciences Stock Up 0.3 %

GILD traded up $0.20 during trading on Thursday, hitting $74.34. The company had a trading volume of 5,194,900 shares, compared to its average volume of 7,335,189. The company has a market capitalization of $92.62 billion, a PE ratio of 205.89, a PEG ratio of 3.37 and a beta of 0.18. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The firm’s 50-day moving average price is $70.41 and its 200 day moving average price is $70.32.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 4.14%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.